Preliminary results of a phase I/II study to determine the safety, tolerability and efficacy of the allogeneic whole cell vaccine in patients with hormone refractory prostate cancer. - Michael,A.; Quatan,N.; Whelan,M.; Kendall,A.; Pandha,H. (Proc Am Soc Clin Oncol, 2003)